Breaking News
BioNTech SE
About BioNTech SE
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond.
Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide.
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent
August 30 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the […]
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
July 28 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, […]
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 27 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and […]
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
June 24 2022
BioNTech SE (Nasdaq: BNTX, “BioNTech”) has reached the next milestone in the establishment of scalable mRNA […]
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
March 9 2022
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
February 22 2022
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Medigene AG (FSE: MDG1, Prime Standard, “Medigene”), a clinical-stage immuno-oncology company focusing […]
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
December 21 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the […]
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY ® in Children 5 to under 12 Years of Age in the European Union
November 26 2021
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for […]
Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana
November 12 2021
Zipline, the global leader in instant logistics, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced […]
Pfizer and Biontech Expand Collaboration with U.S. to Provide 500 Million Additional Covid-19 Vaccine Doses at Not-for-profit Price for Donation to Poorest Countries
September 22 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their […]
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
August 24 2021
Pfizer Inc.and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) approved […]
BioNTech Plans Malaria Vaccine Based on Revolutionary Covid-19 Jab Technology
August 10 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the launch of its Malaria project, which aims to […]
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
August 5 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing […]
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of Covid-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
July 23 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government […]
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
July 22 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent […]
10 Million Doses of mRNA-based COVID-19 Vaccine to be supplied to Taiwan Region
July 12 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced that Fosun Industrial Co., Limited (“Fosun Industrial”), […]
The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-year-olds
June 4 2021
An extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows its […]
Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate
May 24 2021
Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as […]
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
May 11 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food […]
BioNTech to Establish HQ for SE Asia in Singapore
May 10 2021
BioNTech SE today announced plans to expand its global footprint to Asia with the establishment of […]
Pfizer and BioNTech Initiate BLA for FDA Approval of Vaccine
May 10 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application […]
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
May 6 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding […]
Pfizer and BionTech achieve first authorization in the world for a vaccine to combat Covid-19
December 11 2020
Pfizer Inc. and BioNTech SE announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in […]